UPDATED! Guest: IBD’s Kate Stalter from “How To Make Money In Stocks” workshop series. She is also a regular guest on national financial radio shows, and often hosts market video updates in Investors.com Media Center. We also talk with Chris Hill, Director of Communication for The Motley Fool to get...
Things have finally gotten out of control. That statement is based on observing the recent antics of Dennis Kneale, one of the biggest creeps in the financial media today. To be honest, I have usually enjoyed his hard-hitting approach, but he needs a leash put on him. There is no...
Guest: IBD’s Kate Stalter from “How To Make Money In Stocks” workshop series. She is also a regular guest on national financial radio shows, and often hosts market video updates in Investors.com Media Center. We also talk with Chris Hill, Director of Communication for The Motley Fool to get the...
It is one day after the House Energy and Commerce Committee sent a declination letter to the four Congressmen that had been requesting a further review of the questionable FDA ruling for Dendreon’s (DNDN) Provenge, the company’s groundbreaking Prostate cancer drug. Now, a news release shows another beneficial study result...
Just listening to investors or analysts talk these days and it is hard to miss the ongoing chatter about an apparent and impending recession. Some analysts say we are already in one, others point to its arrival in the near future. Regardless of what the experts have predicted, no...
